Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
8.10
+0.58 (7.71%)
At close: Feb 20, 2026, 4:00 PM EST
8.04
-0.06 (-0.70%)
After-hours: Feb 20, 2026, 7:59 PM EST
Organon & Co. Revenue
In the year 2025, Organon & Co. had annual revenue of $6.22B, down -2.92%. Organon & Co. had revenue of $1.51B in the quarter ending December 31, 2025, a decrease of -5.34%.
Revenue (ttm)
$6.22B
Revenue Growth
-2.92%
P/S Ratio
0.34
Revenue / Employee
$621,600
Employees
10,000
Market Cap
2.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.22B | -187.00M | -2.92% |
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 62.58B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
| Biogen | 9.89B |
| Grifols | 8.82B |
| Amarin Corporation | 226.73M |
| Scilex Holding Company | 40.36M |
OGN News
- 9 days ago - Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off - Seeking Alpha
- 9 days ago - Organon & Co. (OGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 - Business Wire
- 23 days ago - Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 - Business Wire
- 24 days ago - Organon Completes Divestiture of JADA® System to Laborie - Business Wire
- 4 weeks ago - Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Benzinga
- 5 weeks ago - Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - Business Wire
- 6 weeks ago - Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway - Business Wire